



SPMC

SALBUTAMOL TABLETS BP 2mg
SALBUTAMOL TABLETS BP 4mg

PRESENTATION:

Salbutamol Tablets BP 2mg:

Packs of 1000 and 2000 tablets

Each Pink, circular, Double convex tablets of 6.5mm diameter with “SPC”, “SPMC” or “DHS” letters on one side and score mark on the reverse contains Salbutamol BP 2mg.

Salbutamol Tablets BP 4mg:

Packs of 1000 tablets

Each Pink, circular, Double convex tablets of 8.0mm diameter with “SPC”, “SPMC” or “DHS” letters on one side and score mark on the reverse contains Salbutamol BP 4mg.

INDICATIONS AND DOSE:

Asthma | other conditions associated with reversible Airways obstruction

Adult: 4 mg 3–4 times a day, maximum single dose 8 mg (but unlikely to provide much extra benefit or to be tolerated), inhalation route preferred over oral Route, use elderly dose for sensitive patients

Elderly: Initially 2 mg 3–4 times a day, maximum single Dose 8mg (but unlikely to provide much extra benefit or to be tolerated), inhalation route preferred over oral Route.

Chronic asthma

Child 3–11 years: 4 mg twice daily

Child 12–17 years: 8 mg twice daily

Adult: 8 mg twice daily

Uncomplicated premature labour (between 22 and 37 weeks of gestation) (specialist supervision in Hospital)

INTRAVENOUS INFUSION

Adult: Initially 10 micrograms/minute, rate increased Gradually according to response at 10-minute intervals until contractions diminish then increase rate slowly until contractions cease (maximum rate 45 micrograms/minute), maintain rate for 1 hour after contractions have stopped, then gradually reduce by 50% every 6 hours, maximum duration 48 hours

MONITORING PARAMETERS:

Monitor BP, heart rate, electrolyte and fluid balance; glucose, lactate and K levels.

BREAST FEEDING:

Inhaled drugs for asthma can be taken as normal during breast-feeding.

CONTRA-INDICATIONS:

When used for uncomplicated premature labour under specialist supervision Abruptio placenta. Antepartum haemorrhage. Cord compression. Eclampsia. History of cardiac disease. Intra-uterine fetal death. Intra-uterine infection. Placenta previa. Pulmonary hypertension. Severe pre-eclampsia. Significant risk factors for myocardial ischemia. Threatened miscarriage.

SIDE EFFECTS:

GENERAL SIDE-EFFECTS

Rare or very rare Akathisia. Vasodilation

Frequency not known Metabolic change

SPECIFIC SIDE-EFFECTS

Common or very common Muscle complaints

Uncommon

When used by inhalation Oral and throat irritation with parenteral use pulmonary oedema

Frequency not known

With parenteral use lactic acidosis (with high Doses). Vomiting

CAUTIONS:

GENERAL CAUTIONS

High doses of beta2 agonists can be dangerous in some children

SPECIFIC CAUTIONS

With intravenous use Mild to moderate pre-eclampsia (when used for uncomplicated premature labour). Suspected cardiovascular disease (should be assessed by a cardiologist before initiating therapy for uncomplicated Premature labour)

PRECAUTIONS & WARNING:

Hyperthyroidism, myocardial insufficiency, arrhythmias, susceptibility to QT-interval prolongation, HTN, DM, glaucoma, hypokalaemia, seizure disorder. Renal impairment. Elderly. Pregnancy and lactation.

INTERACTION:

Increased risk of hypokalaemia with K depleting agents (e.g. corticosteroid, diuretics, xanthines, and digoxin). Increased uterine inertia with halogenated anaesth (IV). Increased risk

of pulmonary oedema with corticosteroids. May antagonise the effect of anti-diabetics. Effects may be altered by guanethidine, reserpine, methyl dopa, TCAs and MAOIs. Increased risk of CV effects with other sympathomimetic agents. Antagonistic effect w/ β -blockers.

OVER DOSAGE:

Symptoms:

Tachycardia, CNS stimulation, tremor, hypokalaemia, hyperglycaemia, lactic acidosis, nausea, vomiting.

Management:

Symptomatic and supportive treatment. May administer activated charcoal. B-blocking agents (e.g. metoprolol) may be given but with extreme caution in asthmatic patients.

STORAGE:

Keep tightly closed in a cool dry place. Protect from light. Keep all medicines away from children. Store below 30⁰ C

*Manufactured by:
State Pharmaceuticals Manufacturing Corporation
No. 11, Sir John Kotalawala Mawatha,
Kandawala Estate,
Ratmalana, Sri Lanka.*